Synapse - referral

Current status

CHMP opinion

Overview

Synapse Labs Pvt. Ltd: re-examination confirms suspension of medicines over flawed studies

On 21 March 2024, EMA’s human medicines committee (CHMP) confirmed its recommendation to suspend or not grant the marketing authorisations of a number of generic medicines tested by Synapse Labs Pvt. Ltd, a contract research organisation (CRO) located in Pune, India. This confirmation concludes the re‑examination requested by the applicants and marketing authorisation holders for some of the medicines concerned.

The CHMP adopted its initial recommendation in December 2023, after a good clinical practice (GCP) inspection which showed irregularities in study data and inadequacies in study documentation and in the computer systems and procedures to manage study data. This raised serious concerns about the data from bioequivalence studies conducted at the CRO. Such studies are carried out to show that a generic medicine releases the same amount of active substance in the body as the reference medicine.

For the majority of the medicines tested by Synapse Labs on behalf of EU companies, the CHMP concluded that supporting data were lacking or insufficient to show bioequivalence and therefore recommended suspending the marketing authorisations of these medicines. For a small number of the medicines, sufficient supporting data were available to demonstrate bioequivalence; marketing authorisations for these medicines were maintained and ongoing marketing authorisation applications could continue.

During the re-examination, the CHMP considered that for one additional medicine¹ sufficient data were available to show bioequivalence; the marketing authorisation for this product can therefore also be maintained.

As a result of the CHMP’s initial opinion and re-examination, the recommendation to suspend medicines for which adequate bioequivalence data are lacking is confirmed. To lift the suspension, companies must provide alternative data demonstrating bioequivalence. Medicines for which ongoing marketing authorisation applications rely solely on data from Synapse Labs will not be granted authorisation in the EU. An updated list of the medicines affected by the procedure is available on EMA’s website.

Some of the medicines that have been recommended for suspension may be of critical importance (e.g., due to a lack of available alternatives) in some EU Member States. National authorities will assess the situation and can postpone the suspension of these medicines for a maximum of two years in the interest of patients. Companies have to submit the required bioequivalence data for these medicines within one year.

EMA and national authorities will continue to work closely together to ensure that studies on EU medicines are carried out to the highest standards and that companies comply with all aspects of good clinical practice. If companies do not meet required standards, authorities will take necessary measures to ensure the integrity of data used to approve EU medicines.

The CHMP's recommendation will now be sent to the European Commission which will issue a legally binding decision in due course.

---

¹ Nibufar. The product has been removed from the list of medicines recommended for suspension.

More about the medicines

The review covered generic medicines authorised or being evaluated via national, decentralised or mutual recognition procedures on the basis of studies conducted by Synapse Labs Pvt. Ltd, located in Pune, India, on behalf of marketing authorisation holders in the EU. EMA’s SPOC Working Party is following the impact of the referral outcome on the supply of critical medicines in EU Member States.

More about the procedure

The review was initiated at the request of the Spanish Agency of Medicines and Medical Devices (AEMPS) under Article 31 of Directive 2001/83/EC in relation to the Agency’s findings of non-compliance with good clinical practice (GCP) at the Synapse Labs Ptv. Ltd. sites in Pune, India.

The review has been carried out by EMA’s Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which has adopted the Agency’s opinion. The CHMP opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.

National authorities will decide if some of the medicines recommended for suspension are of critical importance in their countries.

Synapse Article-31 referral - Synapse Labs Pvt. Ltd: re-examination confirms suspension of medicines over flawed studies

Reference Number: EMA/117559/2024

Key facts

About this medicine

• Approved name:
  Synapse

About this procedure

• Current status:
  CHMP opinion
• Reference number:
  EMEA/H/A-31/1529
• Type:
  Article 31 referrals

  This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

• Authorisation model:
  Nationally authorised product(s)
• Decision making model:
  CHMP-EC

Key dates and outcomes

• CHMP opinion date:
  21/03/2024

All documents

Procedure started

Synapse Article-31 referral - List of medicines concerned by the procedure (Annex I)

Reference Number: EMA/338956/2023 rev. 4

Synapse Article-31 referral - CHMP list of questions to be addressed by Synapse Labs located in Kharadi

Reference Number: EMA/CHMP/304427/2023

Synapse Article-31 referral - Notification

Synapse Article-31 referral - CHMP list of questions to be addressed by applicants and marketing authorisation holders

Reference Number: EMA/CHMP/304426/2023

Synapse Article-31 referral - Timetable for the procedure

Reference Number: EMA/CHMP/304425/2023 Rev. 1

Opinion provided by Committee for Medicinal Products for human Use

Synapse Article-31 referral - Synapse Labs Pvt. Ltd: re-examination confirms suspension of medicines over flawed studies

Reference Number: EMA/117559/2024

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

• Overview - lay-language summary of the stage of the procedure
• Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
• Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
• List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
• Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
• List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
• List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
• Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
• Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
• Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
• Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
• Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
• Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
• Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
• Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.